{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:15:16Z","timestamp":1788369316941,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.blre.2024.101238","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T01:56:15Z","timestamp":1724896575000},"page":"101238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Ven the dose matters: Venetoclax dosing in the frontline treatment of AML"],"prefix":"10.1016","volume":"68","author":[{"given":"Dahniel","family":"Sastow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Levavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Pratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10147","key":"10.1016\/j.blre.2024.101238_bb0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2024.101238_bb0010","author":"Institute, N.C"},{"key":"10.1016\/j.blre.2024.101238_bb0015","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.blre.2024.101238_bb0020","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.leukres.2014.12.013","article-title":"Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction","volume":"39","author":"Ramos","year":"2015","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.blre.2024.101238_bb0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2011.606382","article-title":"Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I\/II study","volume":"53","author":"Al-Ali","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.blre.2024.101238_bb0030","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017015222","article-title":"Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission","volume":"2","author":"Vasu","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2024.101238_bb0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.blre.2024.101238_bb0040","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2024.101238_bb0045","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2024.101238_bb0050","first-page":"2137","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood, J Am Soc Hematol"},{"issue":"2","key":"10.1016\/j.blre.2024.101238_bb0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"10.1016\/j.blre.2024.101238_bb0060","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","article-title":"Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia","volume":"102","author":"Aiba","year":"2023","journal-title":"Ann Hematol"},{"issue":"15","key":"10.1016\/j.blre.2024.101238_bb0065","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-23-0842","article-title":"A metabolically optimized, noncytotoxic low-dose weekly Decitabine\/Venetoclax in MDS and AML","volume":"29","author":"Levitz","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101238_bb0070","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2022-165464","article-title":"Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-na\u00efve patients with acute myeloid leukemia","volume":"140","author":"Willekens","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2024.101238_bb0075","first-page":"290","article-title":"Hypomethylating agents+ venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy-novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country","volume":"11","author":"Mirgh","year":"2021","journal-title":"Am J Blood Res"},{"issue":"1","key":"10.1016\/j.blre.2024.101238_bb0080","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2293512","article-title":"Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia","volume":"29","author":"Cui","year":"2024","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.blre.2024.101238_bb0085","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/ajh.27180","article-title":"Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival","volume":"99","author":"Karrar","year":"2024","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101238_bb0090","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.1182\/blood-2022-162918","article-title":"A phase II study of Azacitidine plus Venetoclax as maintenance therapy in acute myeloid leukemia: durable responses with longer term follow-up","volume":"140","author":"Bazinet","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101238_bb0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.blre.2024.101238_bb0100","series-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","author":"Campos","year":"1993"},{"key":"10.1016\/j.blre.2024.101238_bb0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11523-020-00711-3","article-title":"Targeting apoptosis in acute myeloid leukemia: current status and future directions of BCL-2 inhibition with venetoclax and beyond","volume":"15","author":"Choi","year":"2020","journal-title":"Target Oncol"},{"issue":"2","key":"10.1016\/j.blre.2024.101238_bb0110","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.leukres.2009.05.009","article-title":"BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients","volume":"34","author":"Moon","year":"2010","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.blre.2024.101238_bb0115","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.blre.2024.101238_bb0120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.blre.2024.101238_bb0125","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.blre.2024.101238_bb0130","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2024.101238_bb0135","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.blre.2024.101238_bb0140","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1002\/jcp.28091","article-title":"The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML","volume":"234","author":"Nguyen","year":"2019","journal-title":"J Cell Physiol"},{"issue":"13","key":"10.1016\/j.blre.2024.101238_bb0145","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2024.101238_bb0150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-143200","article-title":"Venetoclax inhibition of pyrimidine synthesis guides methods for integration with Decitabine or 5-Azacytidine that are non-myelosuppressive","volume":"136","author":"Gu","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2024.101238_bb0155","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101238_bb0160","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/01.HS9.0000844928.23775.aa","article-title":"P510: the impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia","volume":"6","author":"DiNardo","year":"2022","journal-title":"HemaSphere"},{"issue":"11","key":"10.1016\/j.blre.2024.101238_bb0165","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1002\/ajh.26692","article-title":"Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A","volume":"97","author":"Pratz","year":"2022","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2024.101238_bb0170","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101238_bb0175","author":"Administration, F.a.D"},{"issue":"2","key":"10.1016\/j.blre.2024.101238_bb0180","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.blre.2024.101238_bb0185","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.27231","article-title":"Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data from eight US academic centers","volume":"99","author":"Abaza","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101238_bb0190","series-title":"A retrospective comparison of abbreviated course \u201c7+ 7\u201d vs standard hypomethylating agent plus venetoclax doublets in older\/unfit patients with newly diagnosed acute myeloid leukemia","author":"Bazinet","year":"2024"},{"key":"10.1016\/j.blre.2024.101238_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107545","article-title":"Less is more: an analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML","volume":"143","author":"Boisclair","year":"2024","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2024.101238_bb0200","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1182\/blood-2023-172882","article-title":"Azacitidine plus Venetoclax maintenance in acute myeloid leukemia produces sustained remissions with low toxicity: results of a phase 2 study","volume":"142","author":"Bazinet","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101238_bb0205","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.1182\/blood-2022-165446","article-title":"Feasibility and safety of outpatient hypomethylating agent (HMA)+ venetoclax (ven) initiation+\/\u2212ramp-up for patients (pts) with newly-diagnosed acute myeloid leukemia (AML)","volume":"140","author":"Shallis","year":"2022","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2024.101238_bb0210","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-23-0842","article-title":"A metabolically optimized, noncytotoxic low-dose weekly decitabine\/venetoclax in MDS and AML","volume":"29","author":"Levitz","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2024.101238_bb0215","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1172\/JCI78789","article-title":"Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes","volume":"125","author":"Saunthararajah","year":"2015","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.blre.2024.101238_bb0220","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/leu.2011.159","article-title":"p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia","volume":"25","author":"Ng","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2024.101238_bb0225","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/asheducation-2013.1.511","article-title":"Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes","volume":"2013","author":"Saunthararajah","year":"2013","journal-title":"Hematology"},{"issue":"24","key":"10.1016\/j.blre.2024.101238_bb0230","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1158\/1078-0432.CCR-21-2139","article-title":"Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions","volume":"27","author":"Zavras","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.blre.2024.101238_bb0235","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine-and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101238_bb0240","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1182\/blood-2023-185379","article-title":"Effective and safe molecular-Pharmacodynamic once weekly dosing of Decitabine and Venetoclax is a highly effective and well-tolerated induction therapy for AML: interim results of a phase 2 trial","volume":"142","author":"Goldfinger","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101238_bb0245","author":"Administration, U.S.F.D"},{"issue":"12","key":"10.1016\/j.blre.2024.101238_bb0250","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.blre.2024.101238_bb0255","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/sj.leu.2403138","article-title":"Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation","volume":"17","author":"Venditti","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101238_bb0260","author":"Cusatis","year":"2024"},{"issue":"2","key":"10.1016\/j.blre.2024.101238_bb0265","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101238_bb0270","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2022-157210","article-title":"Updated results from a phase I\/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia","volume":"140","author":"Short","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101238_bb0275","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2023-187383","article-title":"A randomized phase 2 trial of 28-day (arm a) versus 14-day (arm B) schedule of venetoclax+ Azacitidine in newly diagnosed acute myeloid leukemia patients\u2265 60 years","volume":"142","author":"Borate","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2024.101238_bb0280","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3324\/haematol.2023.282681","article-title":"Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia","volume":"108","author":"Gutman","year":"2023","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2024.101238_bb0285","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.26991","article-title":"Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia","volume":"98","author":"Matthews","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2024.101238_bb0290","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2024.101238_bb0295","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3+ 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.blre.2024.101238_bb0300","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2024.101238_bb0305","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-Centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:57:56Z","timestamp":1731585476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":61,"alternative-id":["S0268960X24000717"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101238","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ven the dose matters: Venetoclax dosing in the frontline treatment of AML","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101238"}}